AC Immune SA
ACIU2.175USD
+0.055+2.59%
交易中 （美東）報價延遲15分鐘
218.39M總市值
虧損本益比TTM
關於 AC Immune SA 公司
AC Immune SA 是一家位於瑞士的臨牀階段生物製藥公司。該公司專注於神經退行性疾病的精準醫療。它設計、發現和開發用於預防、診斷和治療由錯誤摺疊蛋白質引起的疾病的治療和診斷產品。其 SupraAntigen 和 Morphomer 技術平臺可創建抗體、小分子和疫苗，旨在治療廣泛的神經退行性疾病，例如阿爾茨海默病 (AD)。該公司的產品線包括九種治療產品候選藥物（其中五種處於臨牀試驗階段）和三種診斷候選藥物。其主要產品候選藥物是 Crenezumab，一種用於治療阿爾茨海默病的人源化單克隆抗 Abeta 抗體。該公司與羅氏/基因泰克、禮來、百健、楊森製藥、雀巢健康科學研究所、生命分子成像（前身爲 Piramal Imaging）和 Essex Bio-Technology 等製藥公司都有合作。
公司簡介
公司代碼ACIU
公司名稱AC Immune SA
上市日期Sep 23, 2016
CEOProf. Dr. Andrea Pfeifer, Ph.D.
員工數量133
證券類型Ordinary Share
年結日Sep 23
公司地址EPFL Innovation Park
城市LAUSANNE
上市交易所NASDAQ Global Market Consolidated
國家Switzerland
郵編1015
電話41213459121
網址https://www.acimmune.com/
公司代碼ACIU
上市日期Sep 23, 2016
CEOProf. Dr. Andrea Pfeifer, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
Dr. Anke Post, M.D., Ph.D.
Dr. Anke Post, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.80K
--
Dr. Monica Shaw, M.D.
Dr. Monica Shaw, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Roy E. Twyman, M.D.
Dr. Roy E. Twyman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Dr. Monika Buetler, Ph.D.
Prof. Dr. Monika Buetler, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月22日 週二
更新時間: 7月22日 週二
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
持股股東
持股股東
佔比
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
股東類型
持股股東
佔比
Corporation
34.60%
Hedge Fund
21.05%
Individual Investor
3.40%
Investment Advisor/Hedge Fund
2.09%
Investment Advisor
1.20%
Research Firm
1.02%
Bank and Trust
0.03%
Other
36.62%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
116
63.65M
63.39%
-3.52M
2025Q1
122
64.71M
64.45%
-3.00M
2024Q4
118
65.41M
66.11%
-3.57M
2024Q3
115
69.90M
70.65%
+1.39M
2024Q2
111
70.29M
70.97%
+1.59M
2024Q1
107
70.85M
71.52%
-2.28M
2023Q4
109
71.51M
72.19%
+11.62M
2023Q3
121
61.07M
72.18%
-889.36K
2023Q2
131
61.41M
72.77%
+1.91M
2023Q1
140
59.93M
71.03%
-2.26M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
19.82M
19.74%
+300.00K
+1.54%
Mar 31, 2025
DH Capital GmbH & Co. KG
16.32M
16.25%
--
--
Dec 31, 2024
Varuma AG
12.00M
11.95%
--
--
Dec 31, 2024
Affiris AG
6.43M
6.4%
-150.00K
-2.28%
May 31, 2024
Pfeifer (Andrea M. A Ph.D.)
2.96M
2.94%
+534.84K
+22.09%
Dec 31, 2024
Wells Fargo Advisors
997.62K
0.99%
+1.99K
+0.20%
Mar 31, 2025
Renaissance Technologies LLC
803.47K
0.8%
+63.27K
+8.55%
Mar 31, 2025
BlackRock Financial Management, Inc.
642.79K
0.64%
-920.44K
-58.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
393.51K
0.39%
-31.72K
-7.46%
Mar 31, 2025
Northern Trust Global Investments Limited
377.09K
0.38%
-25.95K
-6.44%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
iShares Biotechnology ETF
佔比0.01%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
iShares Health Innovation Active ETF
佔比0%
ALPS Medical Breakthroughs ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
